

MASTERGRAFT® Matrix

Competitive Comparison

MASTERGRAFT® Matrix

MASTERGRAFT® Matrix Competitive Comparison

| | MASTERGRAFT® Matrix | VITOSS® Scaffold Foam (Orthovita, Inc.) | MOZAIK™ Osteoconductive Scaffold (Integra Life Sciences Corp.) | HEALOS® II Bone Graft (DePuy Spine, Inc.) |
|---------------------------------|--|--|--|--|
| Technology Type | Synthetic Bone Graft | Synthetic Bone Graft | Synthetic Bone Graft | Synthetic Bone Graft |
| Mechanism of Action (MOA) | Osteoconduction | Osteoconduction | Osteoconduction | Osteoconduction |
| Pathway to US Market | US 510(k) | US 510(k) | US 510(k) | US 510(k) |
| Indications | Bone Void Filler | Bone Void Filler | Bone Void Filler | Bone Void Filler |
| Product Sizes (Graft Volume) | 5.0cc 10cc 20cc | 5.0cc 6.25cc 10cc 20cc 24cc | 15cc | 2.5cc 5.0cc 8.0cc 10cc 15cc |
| Ceramic Composition | 15% Hydroxyapatite (HA)/ 85% β-TCP | 100% β-TCP | 100% β-TCP | Pure Hydroxyapatite (HA) Particles |
| Ceramic Distribution | Integrated | Integrated | Integrated | Coated |
| Resorption Rate* | Biphasic Composition Provides a Balance of Resorption Rate and Long- Term Stability for Fusion ¹ | May Resorb Too Quickly for Long-Term Stability ² | May Resorb Too Quickly for Long-Term Stability ² | Ceramic Particulate May Resorb Too Quickly ³ |
| Porosity | 87% | 86.6% | 82% | 96.6% |
| Composition (By Mass) | 97.5% Ceramic 2.5% Type I Bovine Collagen | 80% Ceramic 20% Type I Bovine Collagen | 80% Ceramic 20% Type I Bovine Collagen | 29% Ceramic 71% Type I Bovine Collagen |
| Composition (By Volume) | 12% Ceramic 0.7% Collagen | 8.4% Ceramic 5.0% Collagen | 11.3% Ceramic 6.7% Collagen | <0.5% Ceramic 2.9% Collagen |
| Compression Resistant** | Yes | Yes | Yes | No |
| Talking Points | MASTERGRAFT* Matrix is available in kit sizes adaptable to a variety of labeled bone void filling applications including the spine, pelvis, ilium, and extremities. Ceramic composition balances resorption and long-term stability of scaffold. Ceramic is replaced by new bone over time via creeping substitution. Readily absorbs bone marrow aspirate and allows for accurate delivery of included bone-forming cells to the site of implantation. MASTERGRAFT* Matrix is not intended to provide structural support. Supplemental fixation should be used to provide structural support when required. | | | |
| | Data on file. Hing, et al. Comparative performance of three ceramic bone graft substitutes. Spine. 2007; 7:475–490. Krajwattanapong C, et al. Comparison of Healos/bone marrow to Infuse (rhBMP-2/ACS) with | | | |

 Krajwattanapong C, et al. Comparison of Healos/bone marrow to Infuse (rhBMP-2/ACS) with a collagen-ceramic sponge bulking agent as graft substitutes for lumbar spine fusion. Spine. 2005; 30(9):1001–1007.

*Resorption rates may vary due to patient-specific differences and bone biology.

**NOTE: Compression resistance is necessary to preserve space for cell proliferation and growth. When space is preserved, bone-forming cells can produce a greater volume of bone over a larger area of space and ultimately produce larger fusion masses.



Ceramic

Allograft

Medtronic Spinal and Biologics Business

rhBMP

Worldwide Headquarters 2600 Sofamor Danek Drive

Memphis, TN 38132 1800 Pyramid Place Memphis, TN 38132 (901) 396-3133 (800) 876-3133 Customer Service: (800) 933-2635

For more information visit www.myspinetools.com

Please see the package insert for the complete list of indications, warnings, precautions, and other medical information.

Medtronic International Trading SÀRL

Route du Molliau Case postale CH-1131 Tolochenaz

Tel. +41 (0)21 802 70 00 Fax +41 (0)21 802 79 00

VITOSS® Scaffold Foam is a registered trademark of Orthovita, Inc.

MOZAIK[™] Osteoconductive Scaffold is a trademark of Integra Life Sciences Corp.

HEALOS® II is a registered trademark of DePuy Spine, Inc.

www.medtronic.eu